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A B S T R A C T
Aims: In this pilot, placebo-controlled study, we evaluated whether brief administration of teriparatide
(TPTD) in premenopausal women with lower-extremity stress fractures would increase markers of bone
formation in advance of bone resorption, improve bone structure, and hasten fracture healing accord-
ing to magnetic resonance imaging (MRI).
Methods: Premenopausal women with acute lower-extremity stress fractures were randomized to in-
jection of TPTD 20-μg subcutaneous (s.c.) (n = 6) or placebo s.c. (n = 7) for 8 weeks. Biomarkers for bone
formation N-terminal propeptide of type I procollagen (P1NP) and osteocalcin (OC) and resorption col-
lagen type-1 cross-linked C-telopeptide (CTX) and collagen type 1 cross-linked N-telopeptide (NTX) were
measured at baseline, 4 and 8 weeks. The area between the percent change of P1NP and CTX over study
duration is deﬁned as the anabolic window. To assess structural changes, peripheral quantitative com-
puted topography (pQCT) was measured at baseline, 8 and 12 weeks at the unaffected tibia and distal
radius. The MRI of the affected bone assessed stress fracture healing at baseline and 8 weeks.
Results: After 8 weeks of treatment, bone biomarkers P1NP and OC increased more in the TPTD- versus
placebo-treated group (both p ≤ 0.01), resulting in a marked anabolic window (p ≤ 0.05). Results
from pQCT demonstrated that TPTD-treated women showed a larger cortical area and thickness com-
pared to placebo at the weight bearing tibial site, while placebo-treated women had a greater total
tibia and cortical density. No changes at the radial sites were observed between groups. According to
MRI, 83.3% of the TPTD- and 57.1% of the placebo-treated group had improved or healed stress fractures
(p = 0.18).
Conclusions: In this randomized, pilot study, brief administration of TPTD showed anabolic effects that
TPTD may help hasten fracture healing in premenopausal women with lower-extremity stress frac-
tures. Larger prospective studies are warranted to determine the effects of TPTD treatment on stress fracture
healing in premenopausal women.
© 2016 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Stress fractures are the most common overuse injuries of the
lower extremities and occur ﬁve times more frequently in women
than in men [1,2]. In a large study of Finnish military conscripts
involving 102,515 person-years, the strongest risk factor identi-
ﬁed for stress fracture injuries was female gender (hazard ratio = 8.2)
[3]. Vigorous training is associated with a higher risk of stress frac-
tures, with average healing time of up to 12 weeks or more,
depending on the location and severity of the stress injury [4]. Al-
though stress fractures and injuries cause chronic pain and disability,
there are currently no systemic medical treatments available that
may hasten fracture repair and recovery.
Stress fractures are typically diagnosed by clinical signs and symp-
toms, which may be diﬃcult to evaluate due to the subclinical and
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asymptomatic nature of stress fractures [5,6]. In a clinical setting,
imaging techniques are used to conﬁrm and assess the extent of the
injury and monitor fracture healing. An imaging comparison study
showed that the sensitivity of magnetic resonance imaging (MRI),
computed tomography (CT), and bone scans of 50 tibial stress frac-
tures were 88%, 42%, and 74%, respectively [7]. The speciﬁcity and
positive and negative predictive values for MRI were 100%, 100%,
and 62%, respectively, and for CT 100%, 100%, and 26%, respective-
ly. Thus, MRI has become the imaging modality of choice to detect
early and progressive stress fractures because of its high sensitiv-
ity and speciﬁcity [8]. Fredericson et al. applied a diagnostic approach
using aMRI classiﬁcation system to correlate clinical symptomswith
the severity of stress injuries [9]. Accurate assessment of stress frac-
tures is imperative to guide treatment recommendations. Current
therapeutic approaches for lower-extremity stress fractures include:
protective weight-bearing methods, non-weight bearing interven-
tions, immobilization with boot, and/or ultrasound [10]; however,
no systematic medical therapies to improve stress fracture healing
are available at this time.
Daily administration of human recombinant parathyroid hormone
(PTH)(1–34) or teriparatide (TPTD) is currently the only anabolic
therapy approved by the Food and Drug Administration (FDA) for
the treatment of osteoporosis in postmenopausal women and men,
and reduction of risk for vertebral and non-vertebral fractures in
postmenopausal women [11–13]. When TPTD is administered daily,
a rapid rise in bone formation biomarkers and a delayed increase
in bone resorption biomarkers occur [14,15]. This initial increase
in bone formation over resorption biomarkers creates an “ana-
bolic window” [16,17]. Additionally, emerging data suggest that PTH
may have important effects on fracture repair. A placebo-controlled
trial in rodents with closed fractures showed an increase in ana-
bolic activity and improved mineralization after daily TPTD therapy
[18]. In animal studies, PTH improved bone structure, torsion
strength, callus formation, and fracture repair, with a sustained
beneﬁt after discontinuation that may be important in the healing
of lower-extremity stress fractures [19–21].
A number of uncontrolled studies and case series in humans have
shown that the use of TPTD in adults with delayed and nonunion
fractures may hasten bone healing [22–27]. At present, there is only
one randomized-controlled trial after daily treatment of TPTD 20 μg
for 8 weeks demonstrated an acceleration in healing of non-
weight bearing, distal radius fractures in postmenopausal women
[28]. Data related to TPTD use in premenopausal women are limited
[29–33]. Cohen et al. conducted an open-label, pilot study exam-
ining effects of daily therapy of TPTD on bone for 18–24 months
in premenopausal women with unexplained fragility fractures or
idiopathic osteoporosis. Results showed that TPTD increased BMD
of spine and hip, improved trabecular microarchitecture and stiff-
ness at the hip, and bone strength in the radius and tibia in
premenopausal women [31,32]. These data, along with animal
studies, case reports, uncontrolled and limited controlled studies
in humans provide support of the potential beneﬁt of TPTD in frac-
ture healing.
The high incidence of stress fractures in women and extensive
time for stress fractures healing, treatment to hasten fracture repair,
which may reduce the time for recovery, improve bone structure
and healing, and advance fracture care, are of great interest. There-
fore, the objectives of this randomized, placebo-controlled studywere
to examine whether, TPTD injections for 8 weeks (1) increased bone
formation biomarkers in advance of resorption biomarkers, thereby
generating an anabolic window of bone healing, (2) improved bone
structure according to peripheral quantitative computed tomogra-
phy (pQCT) and (3) hastened fracture healing assessed by MRI in
premenopausal women with lower-extremity stress fractures com-
pared to placebo.
Materials and methods
Study subjects
Premenopausal women, aged 21 to 45 years old, with recent
lower-extremity stress fractures diagnosed within 4 weeks of the
screening visit were eligible for enrollment. Exclusion criteria in-
cluded open epiphyses, history of radiation therapy, more than 3
months amenorrhea, current pregnancy or breastfeeding, history
of disorders associated with low bone mass or fractures, and/or use
of medications that affect bone mass. Other inclusion criteria in-
cluded normal baseline alkaline phosphatase, serum calcium,
phosphorus, and thyroid-stimulating hormone levels. All partici-
pants providedwritten informed consent before any study procedure
was performed. This study was performed in the Endocrine Divi-
sion at the Brigham and Women’s Hospital (BWH) and in the NIH-
sponsored, Harvard Clinical and Translational Science Center. The
Partners Institutional Review Board (IRB) approved the protocol (Pro-
tocol No. 2006P000740).
Study drug
Teriparatide™ and placebo injection pens were provided by Eli
Lilly Corporation (Indianapolis, IN, USA). In this randomized, double-
blinded study, injection pens were identical in appearance and
dispensed at baseline and 4 weeks after a negative pregnancy was
conﬁrmed. Participants were trained on how to self-administer the
daily injection.
Study design
Eligible premenopausal women were enrolled and random-
ized by the investigator pharmacist at BWH in a 1:1 ratio to receive
either TPTD 20 μg or matching placebo once daily for 8 weeks. Lab-
oratory tests were collected at baseline, 4 and 8 weeks. Dual-
energy X-ray absorptiometry (DXA) was performed at baseline;
follow-up DXA was not performed as changes in bone are not gen-
erally observed in this short time interval. pQCT was measured at
the radius and unaffected tibia at baseline, 8 and 12weeks. MRI (1.5T)
was performed at baseline and 8 weeks to test whether TPTD has-
tened stress fracture healing. Calcium intakes were calculated and
calcium and cholecalciferol were provided to all subjects to achieve
intakes of 1000mg of elemental calcium and 400 IU vitamin D daily.
All women were instructed to use barrier or hormonal contracep-
tives. A baseline physical examinationwas also completed. Vital signs,
heights (Holtain Stadiometer, Great Britain), and digital scale weights
(Tanita BWB-800, Illinois, USA) were determined, and body mass
index (BMI, kg/m2) was calculated. Study procedures after enroll-
ment included: review of medical history and concomitant
medications, laboratory testing for serum electrolytes, thyroid stimu-
lating hormone, and serum human chorionic gonadotropin (HCG)
to rule out pregnancy at screening, baseline, 4 and 8 weeks.
Bone biomarkers
Biochemical markers of bone turnover were monitored at base-
line, 4 and 8weeks in all study participants. Bone formationmarkers
serum N-terminal propeptide of type I procollagen (P1NP; normal
range 19–83 ug/L) and osteocalcin (OC; 5–25 ng/mL) and bone
resorption markers collagen type-1 cross-linked C-telopeptide
(CTX; 0.11–0.74 ng/mL) and urinary collagen type 1 cross-linked
N-telopeptide (NTX; 5–65 nM BCE/mM Creatinine) were mea-
sured. Serum samples were collected after an overnight fast by
10 am for markers of bone formation (P1NP and OC) and bone re-
sorption (CTX) tominimize diurnal and biological variations of serum
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measures of bone turnover; second void morning fasting urine
samples for the bone resorptionmarker (NTX) were obtained. Serum
and urine samples were aliquoted and stored at −80 degrees Fahr-
enheit until samples were assayed at the time of collection.
P1NP levels were quantiﬁed using a radioimmunoassay [Orion
Diagnostics, distributed by Immunodiagnostic Systems Inc. Foun-
tain Hills, AZ]; both the intra-assay and the inter-assay variations
were <5.5%. The OC levels were measured by homologous equilib-
rium radioimmunoassay (ALPCO Diagnostics, Salem, NH). The intra-
and inter-assay variations for these measures were 5.6% and 5.2%,
respectively. The CTX levels were quantiﬁed using an enzyme
immunoradiometric assay (Nordic Bioscience, distributed by IDS,
Fountain Hills, AZ); with intra-assay and inter-assay variations were
<6.5% each. The urinary NTX level, corrected for creatinine was de-
termined using an enzyme-linked immunosorbent assay (ELISA)
(Osteomark, Wampole Laboratories, Princeton, NJ), with intra-
assay variation of 4.2–5.2% and intra-assay variation of 4.6–7.4%. All
participants’ lab tests were performed in the same assay at NIH-
sponsored, Harvard Catalyst Clinical Research Center (Boston, MA).
Peripheral quantitative computed tomography (pQCT)
To assess systemic changes in bone structure over time, the radius
and unaffected tibia weremeasured at baseline, 8 and 12weeks after
an 8-week treatment period by pQCT (XCT 3000, Stratec, Germany).
The precision errors for the pQCT scanned sites at our research
laboratory were as followed: the distal radius (4% and 33% site)
and unaffected tibia (4%, 38%, 66% site) of the cortical area
(LSC 38% site = 0.45mm2), thickness (LSC 38% site = 0.13mm), density
(LSC 38% site = 12.65 mg/cm3) and total density (LSC 38%
site = 8.97 mg/cm3) [34].
Magnetic resonance imaging (MRI)
Upon enrollment to the study, all participants had MR imaging
to document the presence of a stress fracture. MRI scans of the stress
fracture were performed on a GE Signa 1.5 Tesla scanner with an
Excite upgrade (GE Medical Systems, Milwaukee, WI). A subse-
quent MRI scan was conducted at 8 weeks from baseline to assess
whether fracture healing would occur at 8 weeks rather than the
anticipated 12 weeks [4]. A grading system for the MRI was devel-
oped to evaluate the severity of the lower-extremity stress fracture
[9]. Grade 0 signiﬁed no appreciable lesions of the bone; Grades 1
and 2 indicated a mild-to-moderate periosteal edema and possi-
ble bone marrow edema; and Grades 3 and 4 showed a moderate-
to-severe edema of both the periosteum and marrow. A low-
signal fracture line is visible only in Grade 4 stress fractures. Fractures
that demonstrated a reduction of MRI grade were considered to be
healing and Grade 0 was considered healed. All MRIs were evalu-
ated and scored quantitatively for the grade and extent of stress
fracture at baseline and 8 weeks by a blinded radiologist on this
study.
Adverse events
Adverse events (AEs) during the course of this study were moni-
tored at baseline, 4 and 8 weeks, and deﬁned as any untoward
medical event that occurred or worsened since baseline. Reports
of adverse events were reviewed by a Data Safety Monitoring Board.
Statistical analyses
Data were summarized using means and standard deviations.
The Wilcoxon rank sum test was used to compare the treatment
arms in terms of baseline characteristics, percent change in markers
of bone turnover from baseline, areas under the curve for each
marker, anabolic window, and mean values of DXA at baseline and
pQCT structural changes from baseline. The anabolic window was
deﬁned as the difference between the area under the formation curve
and the area under the resorption curve, in percent change per
month units. To observe changes in MRI scores, deﬁned as the dif-
ference between grades at baseline and at Week 8, Wilcoxon rank
sum test was used. Statistical analysis was performed with SAS
(version 9.3).
Results
Data were collected from April 2009 to July 2012. Of 101 women
screened, 14 premenopausal women were enrolled and random-
ized into two treatment groups TPTD 20-μg (n = 6) or placebo (n = 8)
injections (Fig. 1). One participant withdrew prior to Week 4 visit
due to overseas travel. Thirteen participants were followed for the
complete study period. All participants had normal serum calcium
levels and HCG levels of <1 mIU/mL as tested at screening, base-
line, 4 and 8 weeks. Although one participant in the control group
had vitamin D deﬁciency at baseline [25(OH)D level of 15.8 ng/
ml], no signiﬁcant differences in the baseline mean and follow-up
25(OH)D levels among the TPTD- and placebo-treated premeno-
pausal women with stress fractures were observed. At baseline of
this study, there were no differences in demographics, DXA mea-
surements, and lab results between the TPTD- and placebo-treated
women (Table 1). Location of fractures includes tibia (n = 4), meta-
tarsal (n = 4), femur (n = 3), ﬁbula (n = 1) and calcaneus (n = 1).
Locations of the three femoral stress fractures were at the follow-
ing sites: 1) femoral head and neck, extending to the lesser
trochanter; 2) femoral neck and intertrochanteric region near the
lesser trochanter of the left femur; and 3) right femoral neck region.
Bone turnover biomarkers
Overall changes in biochemical markers of bone turnover from
baseline and 8 weeks are shown in Table 2. In those treated with
TPTD, serum P1NP levels steadily increased after administration of
Figure 1. Subject disposition.
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TPTD at both 4 and 8 weeks (134% ± 52%, p = 0.003 and 180% ± 99%,
p = 0.005, respectively), while OC rapidly increased at 4 weeks
(410% ± 726%, p = 0.03) and doubled above the baseline value at 8
weeks (859% ± 1207%, p = 0.003). At the end of treatment, all bone
formation markers in participants assigned to TPTDwere more than
150% above their baseline value. Placebo-treated participants showed
a modest increase in P1NP and OC levels.
For resorption biomarker CTX, there was a modest, but steady
elevation in serum levels with TPTD (67% ± 86%) in comparison to
placebo (16% ± 41%) (p = 0.28) over 8 weeks. Urinary excretion of
NTX, however, showed a different pattern. Both groups showed slight
elevation in NTX levels at 4 weeks, but NTX levels of the TPTD group
fell below the placebo group at 8 weeks (p = 0.62). By the end of
treatment, NTX levels for TPTD-treated participants were only 25%
above baseline compared to placebo-treated participants who were
55% above baseline. No signiﬁcant changes in resorption markers
were observed during the treatment period (Table 2). The ana-
bolic window was deﬁned as the area between the formation and
resorption curves over time on treatment. Fig. 2 depicts the ana-
bolic window using P1NP and CTX for TPTD and placebo and
indicates a signiﬁcantly greater average area in those treated with
TPTD versus placebo (p = 0.05).
DXA and pQCT
Baseline DXA measures were performed on all participants, and
there were no differences between the TPTD- and placebo-treated
groups. According to pQCT measures, signiﬁcant relationships
between groups as well as within groups were observed over time
after an 8-week treatment (Fig. 3). Compared to placebo, the TPTD-
treated group showed a larger tibia cortical area [median
(interquartile range)] for TPTD [269.52 mm2 (232.6, 278.4)] versus
placebo [256.64 mm2 (244.3, 274.8)] (p ≤ 0.01) (Fig. 3A) and corti-
cal thickness for TPTD [5.58mm (4.8–5.9)] versus placebo [5.25mm
(5.0, 6.0)] (p ≤ 0.01) (Fig. 3B). In the placebo group, the tibia cortical
Table 1
Baseline characteristics of study participants (mean ± SD)
Baseline characteristics Teriparatide
(n = 6)
Placebo
(n = 8)
P
value
Age (years) 32 ± 5.8 31 ± 3.4 –
Weight (kg) 57.4 ± 7.8 61.8 ± 13.2 0.75
Height (cm) 160.0 ± 3.6 160.4 ± 4.6 0.85
Body mass index (kg/m2) 22.4 ± 3.1 24.1 ± 4.9 0.7
Alkaline phosphatase (U/L) 58.3 ± 19.7 60.1 ± 26.3 0.95
Serum P1NP (μg/L) 40.1 ± 25.5 42.4 ± 11.9 0.33
Serum OC (ng/mL) 5.8 ± 5.0 7.9 ± 2.5 0.43
Serum CTX (ng/mL) 0.43 ± 0.2 0.54 ± 0.3 0.44
Urine NTX/creatinine (nM/BCE) 161.7 ± 132.1 356.9 ± 229.2 0.12
Vitamin D 31.8 ± 5.3 32.5 ± 8.9 0.75
Calcium (urinary) 8.6 ± 7.6 10.1 ± 5.7 0.56
Calcium (serum) 9.3 ± 0.4 9.5 ± 0.2 0.16
Parathyroid hormone (PTH) 28.3 ± 4.6 26.6 ± 9.1 0.33
DXA spine (Z-score) −1.2 ± 0.7 −0.7 ± 1.3 0.4
DXA left femoral neck (Z-score) −0.7 ± 1.0 −0.8 ± 1.5 0.94
DXA right femoral neck (Z-score) −0.6 ± 1.0 −0.27±1.1 0.55
DXA left total hip (Z-score) −0.6 ± 0.7 −0.26 ± 1.2 0.58
DXA right total hip (Z-score) −0.5 ± 0.8 −0.09 ± 1.1 0.43
DXA whole body (Z-score) −0.4 ± 0.7 0.46 ± 1.0 0.12
Table 2
Bone turnover marker results at baseline, 4 and 8 weeks
Bone biomarker Time Teriparatide group (n = 6) Placebo group (n = 7) P value
Mean Min Max Mean Min Max
Serum ALP (IU/L) Baseline 58.3 39.0 85.0 60.1 36.0 112.0 0.95
4 weeks 63.3 45.0 94.0 62.7 42.0 105.0 0.43
8 weeks 61.5 61.2 90.0 63.0 41.0 107.0 0.52
Serum P1NP (μg/L) Baseline 40.1 15.8 85.6 42.4 19.4 57.8 0.33
4 weeks 88.5 47.0 197.2 43.9 24.2 62.7 0.003a
8 weeks 103.1 61.2 245.1 47.5 26.1 76.6 0.005a
Serum OC (ng/mL) Baseline 5.8 0.6 13.0 7.9 3.6 10.1 0.43
4 weeks 12.6 1.8 24.3 9.2 5.3 12.8 0.027a
8 weeks 16.8 0.9 30.8 9.6 6.0 12.7 0.003a
Serum CTX (ng/mL) Baseline 0.43 0.26 0.64 0.54 0.28 1.28 0.44
4 weeks 0.61 0.19 1.41 0.43 0.29 0.61 0.43
8 weeks 0.66 0.31 1.28 0.50 0.31 0.80 0.28
Urine NTX (nMBCE/mMCr) Baseline 161.7 40.0 371.0 356.9 94.0 695.0 0.12
4 weeks 205.3 83.3 547.0 384.4 34.0 772.0 0.78
8 weeks 213.3 31.0 540.0 524.4 110.0 1492.0 0.62
P1NP, N-terminal propeptide of type 1 collagen; OC, osteocalcin; CTX, C-telopeptide of type 1 collagen; urine NTX, N-telopeptide of type 1 collagen, corrected for mM creatinine.
a Bone formation markers, P1NP and OC, were signiﬁcantly different (p-value < 0.05) at 4 and 8 weeks.
Figure 2. Anabolic window is the shaded area between P1NP and CTX. Compari-
son of the area between P1NP curve and the CTX curve in premenopausal women
with stress fractures treated with Teriparatide or placebo. The graph shows a sig-
niﬁcantly larger mean area in the Teriparatide group (145.82 ± 123.0) compared to
the placebo group (5.99 ± 48.4) (p = 0.05).
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density was slightly greater at the 38% tibia site at 8 weeks
[1211.10 mg/cm3 (1162.1, 1228.2)] (p = 0.01) and 12 weeks
[1214.30 mg/cm3 (1167.8, 1230.0)] (p = 0.04) compared to the
TPTD-group [1199.25 mg/cm3 (1166.9, 1210.4) and 1201.5 mg/cm3
(1165.9, 1211.2), respectively] (Fig. 3C). There was an unexpected,
larger total tibia density at the 38% site at 8 weeks in the placebo-
[979.00mg/cm3 (914.17, 1027.0)] compared to TPTD-treated women
[968.30 mg/cm3 (873.7, 995.9)] (p ≤ 0.05) (Fig. 3D). Within groups,
TPTD-treated participants showed a signiﬁcant increase from base-
line to 8 weeks at the tibia cortical area (p ≤ 0.03) and cortical
thickness (p ≤ 0.03). Placebo-treated participants demonstrated a
slight signiﬁcant rise in tibia cortical density (p ≤ 0.02) and total tibia
density (p ≤ 0.03). There were no differences between groups at the
other tibia sites (4% and 66%) or non-weight bearing distal radius
(4% and 33%) during the study period.
Magnetic resonance imaging
Table 3 shows the location of the stress fractures and the MRI
results of the severity of the stress fractures at baseline and fol-
lowing 8 weeks of TPTD vs. placebo. Fractures grades were similar
between treatment and placebo groups at baseline (p = 0.21). In the
TPTD-treated group, 83.3% of women had healed (Grade 0) and im-
proved fracture repair compared to 57.1% of women in the placebo-
treated group; however, these differences were not signiﬁcant
(p = 0.18). Of those who did not heal completely but showed im-
provement in fracture healing, 50% were in the TPTD-treated group,
while 29% were in the placebo-treated group. Lastly, no change in
bone healing was observed in 43% of participants who received
placebo, while only 17% of participants who received TPTD showed
no response. No signiﬁcant correlation was found between baseline
Figure 3. Peripheral quantitative computed tomography (pQCT) images of the 38% tibia, unaffected site at baseline, 8 and 12 weeks between teriparatide and placebo groups.
Treatment was administered from baseline to 8 weeks. * Indicates = 0.05, between groups. ** Indicates = 0.05 within groups, over time.
Table 3
MRI grade at baseline and 8 weeks
Subject Location of fracture MRI baseline MRI 8 weeks MRI difference
Teriparatide
1 Femur 4 4 0
2 Tibia 3 2 −1
3 Tibia 2 0 −2
4 Femur 2 0 −2
5 Metatarsal 4 2 −2
6 Metatarsal 4 1 −3
Placebo
1 Fibula 1 1 0
2 Tibia 2 2 0
3 Femur 3 3 0
4 Metatarsal 1 0 −1
5 Metatarsal 4 3 −1
6 Tibia 2 0 −2
7 Calcaneus 3 1 −2
Grades 1 and 2 indicate a mild-to-moderate periosteal edema. Grades 3 and 4 showed
moderate-to-severe edema of both the periosteum and marrow. A low-signal frac-
ture line is visible in Grade 4 stress fractures. A reduction of MRI grade was considered
to be healing; Grade 0 was considered healed. MRI difference was deﬁned as the
difference between MRI score at baseline and at 8 weeks.
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grade and fracture improvement, either overall according to treat-
ment group or by absolute or proportional improvement in stress
fracture healing (p > 0.13). There was no signiﬁcant relationship
between the grade of the stress fracture and improvement or healing.
Adverse events
There were eight reports of AEs. Six of the eight AEs were minor
reports of slight bruising at the injection site, which were as ex-
pected and resolved in a few days. One subject reported a pea-
sized bump below the site of stress fracture; MRI imaging of this
site did not show any abnormalities. One placebo-assigned partic-
ipant reported light-headedness during the day that resolved within
4 weeks of treatment.
Discussion
This prospective, placebo-controlled pilot study was designed
to determine whether short-term, daily TPTD treatment, in-
creased bone formation markers in advance of resorption markers,
produced early changes in bone structure and hastened stress frac-
ture healing. Our data did show an increase in bone formation
markers P1NP and OC after daily administration of TPTD, result-
ing in a signiﬁcant anabolic window response (p = 0.05) [35]. These
rises in P1NP and OC within 1 to 3 months indicate early stimula-
tion of bone formation activity consistent with TPTD’s anabolic effects
on bone [36,37]. pQCT demonstrated a greater tibia cortical area and
thickness at the 38% tibia site after 8 weeks with TPTD treatment
compared to placebo. While compared to the TPTD group, the
placebo group demonstrated a larger tibia cortical density and total
tibia density at 8 weeks. While according to MRI, a larger percent
of women with stress fractures treated with TPTD compared with
placebo showed improvement in healing at 8 weeks, this study did
not have suﬃcient power to demonstrate a signiﬁcant hastening of
stress fracture healing (p = 0.18). These preliminary data suggest that
short-term TPTD treatment may support the improvement of frac-
ture healing in premenopausal women with lower-extremity stress
fractures.
Premenopausal women brieﬂy treated with TPTD compared to
placebo showed a rapid increase in bone formation markers P1NP
by 134% and OC by 410% from baseline to 4 weeks. At 8 weeks, P1NP
and OC were both 150% above baseline in the TPTD- compared to
the placebo-treated women. These bone formation biomarkers were
statistically signiﬁcant between groups as early as 4 and 8 weeks.
These results support previous ﬁndings of increases in P1NP and
OC biomarkers during daily TPTD therapy among postmenopausal
women and men, with potential longer-term anabolic beneﬁts on
bonemass [14,38,39]. After a brief 8-week TPTD treatment, our pilot
study showed an immediate robust response to markers of bone
formation as early as 4 weeks followed by a delayed response in
bone resorption reﬂects the anabolic window, as described by Rubin
and Bilezikian [16,17]. The shaded area between P1NP and CTX over
time reveals a signiﬁcantly larger anabolic window in those treated
with TPTD compared with those treated with placebo (Fig. 2). Our
preliminary data suggest that brief, daily treatment of TPTD results
in a robust anabolic window effect, which may support the frac-
ture healing process in premenopausal womenwith lower-extremity
stress fractures. A study of premenopausal women with
glucocorticoid-induced osteoporosis displayed a signiﬁcant rise in
CTX concentration after 6 months of daily TPTD-treatment [30]. Our
study showed after 8 weeks, a modest rise of CTX levels that sug-
gests that CTX levels may increase over time. NTX levels were
elevated in both TPTD and placebo groups at 4 weeks, followed by
a decrease in the TPTD group but not the placebo group at 8 weeks.
This may be due to a placebo-assigned participant who had high
NTX levels both at baseline and at 8 weeks (669 and 1492 nM BCE/
mM, respectively), which is well above the normal premenopausal
range in the absence of a fracture. Although TPTD has been shown
to have an effect on overall bone remodeling, there were no sig-
niﬁcant changes in bone resorptionmarkers in our study, whichmay
be due to the short duration of the study treatment [14,36].
After 8 weeks of observation, our study demonstrated a signiﬁ-
cantly larger tibia cortical area and thickness in the TPTD-treated
group compared to the placebo-treated group according to pQCT.
Results from the Denosumab and Teriparatide Administration (DATA)
study showed an increase in tibia cortical thickness after combi-
nation treatment of TPTD and denosumab but not with TPTD alone
over 24months in postmenopausal women [40]. In contrast to DATA,
our pilot study showed a greater tibia cortical thickness in the TPTD
group only after a brief 2-month administration compared to the
placebo group [41]. An uncontrolled pilot study examining the use
of TPTD in premenopausal women with IOP showed no change in
cortical thickness or density but did show an increase in trabecu-
lar density and microarchitecture at the tibia after 18 months [32].
Differences between these studies and ours were the short-term
study, treatment intervention of our study and the use of high res-
olution pQCT (HR-pQCT) versus pQCT to assess the bone structural
changes. Studies have shown that pQCT provides more robust mea-
sures and correlations of cortical bones parameters at proximal
scanning sites at the distal radius and tibia than HR-pQCT [42]. In
addition, our data revealed an unexpected difference between the
placebo-treated group compared to the TPTD-treated group, showing
a greater cortical density and total tibia density in participants treated
with placebo at 8 weeks. A possible explanation for this observa-
tion is that weight bearing on the unaffected lower-extremity may
have resulted in larger tibia cortical and total density as more par-
ticipants in the placebo groups relied on crutches. Our study did
not reveal any other differences between groups at other radial or
tibial sites according to pQCT during the study period. The greater
tibia cortical area and thickness at the 38% tibia site in the TPTD
versus placebo groups at 8 weeks suggests some potential beneﬁt
of TPTD. Larger randomized studies are necessary to reassess and
validate the use of TPTD in premenopausal women, particularly in
those with lower-extremity stress fractures.
To monitor fracture healing, a grading systemwas used to assess
the severity of the lower extremity stress fractures at baseline and
8 weeks. At the end of 8 weeks, 83% in the TPTD group showed im-
proved healing of stress fractures compared with 57% in the placebo
group (p = 0.18). Of those assigned to placebo, 3 of the 7 partici-
pants (42.9%) showed no change in stress fracture healing, while
only 1 participant (16.7%) of the 6 participants assigned to TPTD
was unresponsive to treatment. Half of the women in the TPTD-
treated group had Grade 4 stress fractures at baseline. Of these
women, 2 participants showed an improvement in fracture healing
(Grade 4 to 2 and Grade 4 to 1). Of the placebo-treated group, only
one participant had a Grade 4 stress fracture, with slight improve-
ment (Grade 4 to 3). Due to the variance and severity of stress
fractures in our pilot study, statistical tests were used to adjust for
the heterogeneity of these fractures. Results, however, showed no
statistically signiﬁcant difference in healing among these 13 par-
ticipants, but appears to show an encouraging trend. In 102
postmenopausal womenwith distal radius fractures, one study dem-
onstrated an acceleration of fracture healingwith TPTD (20 μg) versus
placebo (7.4 versus 9.1 weeks, respectively) [28,43]. Although our
study did not show any difference in fracture healing between groups,
these studies suggest that with larger studies, TPTD is a promising
potential therapy to speed up fracture healing in younger premeno-
pausal women.
At present, there are no randomized trials exclusive to premeno-
pausal women and daily TPTD treatment. This pilot study, therefore,
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is currently the only placebo-controlled trial in premenopausal
women that addresses the anecdotal use of TPTD as a therapy to
improve fracture healing to date. A limitation of this study is the
small sample size. Although we implemented extensive recruit-
ment efforts, enrolling study participants after an acute stress injury
was a challenge since stress fractures may not be clinically evident
early in the course of their presentation. In a case study of 295 mil-
itary recruits, 30% of these recruits were found to have stress fractures
and of those who had stress fractures of the femur, 69% were as-
ymptomatic [5]. In another study, the time from injury to diagnosis
took an average of 13.4 weeks among 320 athletes [44]. Our inclu-
sion criteria required eligible participants to be enrolled within 4
weeks of fracture onset, which proved challenging, but necessary
for the study design. We acknowledge that a small sample size may
have led to increased variability in primary endpoints and limited
the power to demonstrate acceleration of bone healing in re-
sponse to TPTD. Although great efforts were made to extend this
study and continue recruitment this was not possible form the
funding agency.
Conclusion
Our pilot study shows some evidence of improvement in stress
fracture healing on MRI in the TPTD- compared to the placebo-
treated group; however, results were not signiﬁcant at 8weeks. These
data use TPTD as a potential treatment option in premenopausal
women with lower-extremity stress fractures. This pilot study dem-
onstrated that TPTD-treated premenopausal women with lower-
extremity stress fractures had a signiﬁcantly greater anabolic window
compared to placebo-treated women. The TPTD-treated group
showed a greater tibia cortical area and thickness compared to the
placebo-treated group as early as 8weeks of treatment, while a larger
tibia cortical and total tibia density were observed in the placebo-
treated group. Given the potential clinical use of TPTD to accelerate
fracture healing, larger prospective, placebo-controlled studies are
needed to validate the effects of TPTD versus placebo in womenwith
lower-extremity stress fractures.
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